Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2/3

NCT06028737 is registered in ClinicalTrials.gov with Ukrainian Society of Clinical Oncology as lead sponsor.

NCT NCT06028737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06028737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2/3
Lead sponsor
Ukrainian Society of Clinical Oncology
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 25, 2025
Completion date
December 31, 2032
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma, advanced gastric carcinoma, advanced gastroesophageal junction adenocarcinoma, chemotherapy, gastrectomy, gastrectomy for gastric cancer, gastric (cardia, body) cancer, gastric adenocarcinoma, gastric cancer, gastric neoplasm, gastric resection, gastroesophageal cancer, gastroesophageal junction adenocarcinoma, gastrointestinal cancer, stomach cancer, stomach neoplasm